BioSpace News Archive

Founded in 2013, Aerobiotix, a rapidly growing global medical company has raised a $25 million of growth equity financing. The round was led by Vivo Capital with participation by Asahi Kasei Ventures. The new funding will be used to accelerate sales, marketing, and new product development. T

Oncologists at University Hospitals have two new powerful tools in the fight against cancer following the announcement that Abecma & Breyanzi, from Bristol Myers Squibb, are currently being used to treat patients at UH Seidman Cancer Center.

Efferent Labs and W. L. Gore & Associates announced an expansion of their collaboration to explore the utility of Gore materials in Efferent’s “Living Informatics” CytoComm™ platform.

At 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.

BELKIN Laser, the Israel-based start-up bringing a fast, automated and non-invasive glaucoma laser treatment to market announced today that it has completed enrollment in its GLAUrious randomized controlled trial.

Life Spine won a second ruling barring Aegis Spine, Inc. from marketing, selling, or distributing devices in its AccelFix-XT product line.

Organization Presents Roadmap Forward to Address the National Crisis Post-Pandemic for 61 Million Americans with Disabilities including Thousands Living in DC, Maryland and Virginia.

Medly Pharmacy, a full-service digital pharmacy that offers free same-day prescription delivery, announced the opening of their new Manhattan location located at 1868 3rd Ave, New York, NY 10029.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, May 13th, 2021 to report its first quarter 2021 financial results and provide a corporate update.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended March 31, 2021.